CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors.

ABSTRACT: Background: Homologous recombination deficiency (HRD) is a common molecular characteristic of genomic instability, and has been proven to be a biomarker for target therapy. However, until now, no research has explored the changes in the transcriptomics landscape of HRD tumors. Methods: The HRD score was established from SNP array data of breast cancer patients from the cancer genome atlas (TCGA) database. The transcriptome data of patients with different HRD scores were analyzed to identify biomarkers associated with HRD. The candidate biomarkers were validated in the gene expression omnibus (GEO) database and immunotherapy cohorts. Results: Based on data from the gene expression profile and clinical characteristics from 1310 breast cancer patients, including TCGA data

SUBMITTER: Shi Z 

PROVIDER: S-EPMC8210593 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature